Combined chemotherapy with carboplatin and paclitaxel (CP) is widely used overseas as a 2nd line chemotherapy for metastatic melanoma. We report the results from 9 stage IV melanoma patients treated with CP therapy who had progressed on a dacarbazine-containing regimen. Of the 9 patients, one achieved a partial response (PR), 3 had stable disease (SD), and 5 had progressive disease (PD). The median progression free survival (PFS) was 2.8 months and the median overall survival was 10.6 months for all patients. The regimen had clinically acceptable toxicity. Four (44%) of the patients achieved disease control under CP therapy. In addition, the PFS of patients with controlled disease (PR and SD) were 7.0 to 11.6 months, significantly longer than those of PD patients. These results implied that CP therapy could be an option in Japan for salvage chemotherapy for stage IV melanoma.
View full abstract